IDEAYA Biosciences vs Zymeworks
IDYA and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDYA and ZYME compare
IDEAYA Biosciences is the larger company, worth 1.6 times as much as Zymeworks ($3.0B against $1.9B).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −74.8% at IDEAYA Biosciences.
Zymeworks scores higher on the StockData Score (10 against 9 for IDEAYA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDYA | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $1.9B |
| Share price | $31.49 | $26.47 |
| Change, 1 year | −1.6% | 34.5% |
| Change, 5 years | 35.6% | 33.6% |
| Beta (5Y) | 0.77 | 0.82 |
| Employees | 145 | 264 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 50.9× |
| P/S | 13.0× | 7.1× (better) |
| P/B | 2.5× (better) | 7.3× |
| EV/EBITDA | – | 40.3× |
| FCF yield | −3.7% (better) | −6.0% |
| Fair value | $29.47 | $11.98 |
| Margin of safety | −6.9% (better) | −121% |
| Growth | ||
| Revenue growth (TTM) | – | 97.8% |
| Revenue growth, 5Y average | 62.1% (better) | 22.2% |
| Profitability | ||
| Operating margin | −92.7% | 16.6% (better) |
| Net margin | −74.8% | 16.3% (better) |
| FCF margin | −48.6% | −42.4% (better) |
| Return on equity | −16.2% | 15.0% (better) |
| Return on invested capital | −51.9% | 21.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.45 (better) | 3.30 |
| Altman Z-score | 15.79 (better) | 0.75 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.8% |
| Shareholder yield | 0.00% | 8.8% (better) |
| Ownership | ||
| Held by institutions | 106% | 98.1% |
| Held by insiders | 0.83% | 58.9% |
| Insider net buying, 12 months | $281K (better) | −$5.0M |
| Short interest, % of float | 8.6% | 20.3% |
Go deeper
- IDYA stock overview
- IDYA income statement
- IDYA valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.